Cisplatin chemotherapy and renal function

Cisplatin has been a mainstay of cancer chemotherapy since the 1970s. Despite its broad anticancer potential, its clinical use has regularly been constrained by kidney toxicities. This review details those biochemical pathways and metabolic conversions that underlie the kidney toxicities. A wide ran...

Full description

Saved in:

Bibliographic Details
Published in	Advances in cancer research Vol. 152; pp. 305 - 327
Main Authors	Zhang, Jie, Ye, Zhi-wei, Tew, Kenneth D., Townsend, Danyelle M.
Format	Journal Article
Language	English
Published	United States Elsevier Inc 2021
Subjects	Alkylating agent Antineoplastic Agents - pharmacology Antioxidants Antioxidants - metabolism Bioactivation Cisplatin Cisplatin - metabolism Cisplatin - pharmacology Glutathione Glutathione - metabolism Glutathione - pharmacology Glutathione S-transferases Humans Kidney Kidney - metabolism Neoplasms - drug therapy Neoplasms - metabolism Nephrotoxicity Oxidative Stress Redox pathways Transporters Antioxidants Alkylating agent Bioactivation Redox pathways Transporters Glutathione S-transferases Nephrotoxicity Cisplatin Kidney Glutathione
Online Access	Get full text
ISSN	0065-230X 2162-5557 2162-5557
DOI	10.1016/bs.acr.2021.03.008

Cover

More Information
Summary:	Cisplatin has been a mainstay of cancer chemotherapy since the 1970s. Despite its broad anticancer potential, its clinical use has regularly been constrained by kidney toxicities. This review details those biochemical pathways and metabolic conversions that underlie the kidney toxicities. A wide range of redox events contribute to the eventual physiological consequences of drug activities.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0065-230X 2162-5557 2162-5557
DOI:	10.1016/bs.acr.2021.03.008